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Abstract
Introduction Notch signaling has been implicated in the
regulation of cell-fate decisions such as self-renewal of adult
stem cells and differentiation of progenitor cells along a
particular lineage. Moreover, depending on the cellular and
developmental context, the Notch pathway acts as a regulator of
cell survival and cell proliferation. Abnormal expression of Notch
receptors has been found in different types of epithelial
metaplastic lesions and neoplastic lesions, suggesting that
Notch may act as a proto-oncogene. The vertebrate Notch1 and
Notch4 homologs are involved in normal development of the
mammary gland, and mutated forms of these genes are
associated with development of mouse mammary tumors.
Methods In order to determine the role of Notch signaling in
mammary cell-fate determination, we have utilized a newly
described in vitro system in which mammary stem/progenitor
cells can be cultured in suspension as nonadherent
'mammospheres'. Notch signaling was activated using
exogenous ligands, or was inhibited using previously
characterized Notch signaling antagonists.
Results Utilizing this system, we demonstrate that Notch
signaling can act on mammary stem cells to promote self-
renewal and on early progenitor cells to promote their
proliferation, as demonstrated by a 10-fold increase in
secondary mammosphere formation upon addition of a Notch-
activating DSL peptide. In addition to acting on stem cells,
Notch signaling is also able to act on multipotent progenitor
cells, facilitating myoepithelial lineage-specific commitment and
proliferation. Stimulation of this pathway also promotes
branching morphogenesis in three-dimensional Matrigel
cultures. These effects are completely inhibited by a Notch4
blocking antibody or a gamma secretase inhibitor that blocks
Notch processing. In contrast to the effects of Notch signaling
on mammary stem/progenitor cells, modulation of this pathway
has no discernable effect on fully committed, differentiated,
mammary epithelial cells.
Conclusion These studies suggest that Notch signaling plays a
critical role in normal human mammary development by acting
on both stem cells and progenitor cells, affecting self-renewal
and lineage-specific differentiation. Based on these findings we
propose that abnormal Notch signaling may contribute to
mammary carcinogenesis by deregulating the self-renewal of
normal mammary stem cells.
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Introduction
Stem cells in adult tissues are characterized by their ability
to undergo self-renewal and multilineage differentiation [1].
The elucidation of pathways that govern stem cell functions
is essential for understanding normal development and org-
anogenesis. Moreover, there is increasing evidence that
defects in these pathways play an important role in carcino-
genesis [2]. The isolation of stem cells from the mammary
gland in humans and rodents has been hindered by the lack
of identified specific cell surface markers. Furthermore,
investigation of the mechanisms underlying cell-fate deci-
sions in mammary stem/progenitor cells has been limited
by the lack of suitable in vitro culture systems, which main-
tain these cells in an undifferentiated state [3].
We have recently described an in vitro culture system that
allows for the propagation of primary human mammary epi-
thelial stem cells and progenitor cells in an undifferentiated
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state, based on their ability to proliferate in suspension as
spherical structures, which we have termed 'nonadherent
mammospheres' [4]. As has previously been described for
neuronal stem cells and progenitor cells cultured as neuro-
spheres [5], we have demonstrated that mammospheres
are composed of stem cells and progenitor cells capable of
self-renewal and multilineage differentiation [4]. We have
utilized this system to investigate the role of Notch signal-
ing in mammary cell-fate determination.
In other systems, Notch signaling has been shown to play
an important role in cell-fate determination, as well as in cell
survival and proliferation [6,7]. The Notch proteins, repre-
sented by four homologs in mammals (Notch1–Notch4),
interact with a number of surface-bound or secreted lig-
ands (Delta-like 1, Delta-like 3, Delta-like 4, Jagged 1 and
Jagged 2) [8-10]. These interactions are modulated by
modifier proteins from the Fringe family (Lunatic, Manic,
and Radical Fringe) [11]. Upon ligand binding, Notch
receptors are activated by serial cleavage events involving
members of the ADAM protease family, as well as an
intramembranous cleavage regulated by gamma secretase
(presinilin). This intramembranous cleavage is followed by
translocation of the intracellular domain on Notch to the
nucleus, where it acts on downstream targets [11]. The ver-
tebrate Notch4 gene has been shown to be involved in nor-
mal mammary development [12]. In vitro, overexpression of
a constitutively active form of Notch4 inhibits differentiation
of normal breast epithelial cells [13]. In vivo, transgenic
mice expressing a constitutively active form of Notch4 fail
to develop normal mammary glands and subsequently
develop mammary tumors [14]. These studies suggest the
involvement of Notch signaling in normal breast develop-
ment, and that alterations in Notch signaling may play a role
in breast cancer development [15,16].
Materials and methods
Dissociation of mammary tissue
Normal breast tissue from reduction mammoplasties was
dissociated mechanically and enzymatically, as previously
described [17]. Cells were sieved sequentially through a
100 µm cell strainer and a 40 µm cell strainer (BD Falcon,
Palo Alto, CA, USA) to obtain a single cell suspension.
Mammosphere culture
Single cells were plated on ultralow attachment plates
(Corning, Acton, MA, USA) at a density of 20,000 viable
cells/ml in primary culture and a density of 1000 cells/ml in
passages. Cells were grown in serum-free mammary epi-
thelial growth medium (BioWhittaker, Rockland, ME, USA),
supplemented with B27 (Invitrogen, Carlsbad, CA, USA)
and 10 ng/ml epidermal growth factor (BD Biosciences,
Palo Alto, CA, USA). The bovine pituitary extract was
excluded.
Mammospheres were collected by gentle centrifugation
(800 rpm) after 7–10 days, and were dissociated enzymat-
ically (10 min in 0.05% trypsin, 0.53 mM EDTA-4Na; Invit-
rogen) and mechanically, using a fire-polished Pasteur
pipette. The cells obtained from dissociation were sieved
through a 40 µm sieve and analyzed microscopically for sin-
gle cellularity. Cells plated at low densities (1000 cells/ml)
were grown in conditioned medium from high-density pri-
mary cultures in suspension.
Differentiating culture conditions
Single cell suspensions were plated on collagen-coated
plates at a density of 2000 viable cells/10 cm diameter
dish. Cells were grown in Ham's F-12 medium (BioWhit-
taker) with 5% fetal bovine serum (FBS), 5 µg/ml insulin, 1
µg/ml hydrocortisone, 10 µg/ml cholera toxin (Sigma, St
Louis, MO, USA), 10 ng/ml epidermal growth factor (BD
Biosciences) and 1 × Pen/Strep/Fungizone Mix (BioWhit-
taker). Three-dimensional cultures in Matrigel were estab-
lished as previously described [18].
Immunostaining
To assess the lineage composition of the colonies, cells
were fixed on plates for 20 min in methanol, at -20°C, and
were then stained using Peroxidase Histostain-Plus and
Alkaline-phosphatase Histostain-Plus kits (Zymed, South
San Francisco, CA, USA), according to the manufacturer's
protocol. The ductal–alveolar structures were fixed in
Matrigel in 4% neutral formalin, and treated with 1 mg/ml
proteinase K for 10–15 min at room temperature, prior to
staining. For immunostaining in Matrigel, all antibody incu-
bations were for 60–90 min at 37°C, and washes were for
20 min at 37°C, with a final overnight wash at 4°C.
The primary antibodies – epithelial-specific antigen and
cytokeratin 18 for epithelial cells, CD10 and cytokeratin 14
(Novocastra, Newcastle-upon-Tyne, UK) for myoepithelial
cells – were used at the dilutions indicated by the manufac-
turer. The Notch4 antibody was used at a dilution of 1:50
for immunohistochemistry and of 1:20 for immunostaining
structures within Matrigel. AEC and DAB (Zymed) were
used as substrates for peroxidase, and NBT/BCIP (Gibco/
BRL, Gaithersburg, MD, USA) was used for alkaline phos-
phatase. FITC-labeled and Texas-red labeled secondary
antibodies (Jackson Labs, West Grove, PA, USA) were
used for fluorescent microscopy.
Luciferase gene reporter assay
MCF-7 cells were grown in RPMI 10% FBS on tissue cul-
ture-treated plastic dishes. Cells were collected by trypsini-
zation and RNA was isolated as previously described and
used to test expression of Notch1 and Notch4 by RT-PCR.
MCF-7 cells expressed both Notch1 and Notch4 so they
were further used for the gene reporter assay. Expression
of Notch4 in MCF-7 cells was also confirmed byAvailable online http://breast-cancer-research.com/content/6/6/R605
R607
immunohistochemistry. The staining was mostly nuclear
and cytoplasmic, although membrane staining was also
present, confirming detectable levels of active Notch4 in
MCF-7 cells.
The specificity of the antibody was tested by the manufac-
turer via western blotting using cell lysates from a variety of
human cancer cell lines (Jurkat cells, HeLa, H4, etc.) that
express all four homologs of Notch. The antibody was
raised against a synthetic peptide that does not show
sequence similarity with any of the other Notch members,
as shown by Blast search analysis. Using the Lipo-
fectamine–Plus kit (Promega, Madison, WI, USA), cells
were co-transfected with pcDNA3 (Invitrogen) and a
pGL3-promoter vector (Promega) containing a Hes-1 pro-
moter-derived sequence upstream of luciferase, according
to the manufacturer's protocol. Stable transfection was
achieved by selecting with 800 µg/ml Geneticin (Gibco/
BRL).
Cells were incubated for 4, 8 and 16 hours in the presence
of agonists or antagonists of Notch signaling as follows:
blocking Notch4 antibody (Santa-Cruz, Santa Cruz, CA,
USA) was used in dilutions of 1:100, 1:50, 1:25 and 1:10,
gamma secretase inhibitor (GSI) type I (Z-Leu-Leu-Nle-
CHO; Calbiochem, San Diego, CA, USA) was used at 20
µM, 10 µM, 5 µM, 1 µM, 100 nM and 10 nM concentration,
and the DSL peptide (CDDYYYGFGCNKFCRPR;
Research Genetics, Huntsville, AL, USA) was used at 10
µM, 1 µM, 100 nM, 10 nM and 1 nM. The control scram-
bled peptide (DYGKRCYGCFPDYFNCR) was used at 10
µM concentration. Dimethylsulfoxide 1:50 was used as a
control for GSI. Direct evidence that GSI blocks Notch4
and Notch1 cleavage in vitro has been provided previously
[19].
The treatment with antagonist involved incubating for 1
hour at 37°C, prior to treatment with the DSL peptide. Incu-
bation of the antibody with the peptide against which it was
raised (Santa Cruz) was carried out at antibody to peptide
ratios of 1:1, 1:2. 1:3 and 1:4 (vol:vol). Luciferase activity
was assessed using the Luciferase assay system
(Promega) and a Turner Designs luminometer TD-20/20
(Turner Designs, Sunnyvale, CA, USA).
Treatment with Notch agonists and antagonists
Treatment with Notch agonists and antagonists was car-
ried out as described for the reporter assay. The DSL pep-
tide was used at a concentration of 100 nM. The
recombinant Delta 1 Fc ligand was prepared and used as
previously described [20]. Anti-human Fc antibody (Jack-
son Labs) was added to the medium at 1:100 dilution, to
cluster the recombinant ligand–receptor complexes. The
blocking Notch4 antibody was used at a dilution of 1:50,
and the GSI at a concentration of 5 µM. In experiments in
which treatment was applied for longer than 48 hours, it
was added every 2 or 3 days when the medium was
changed. The Notch4 antibody and antigenic peptide used
for treating cells in culture did not contain sodium azide.
FACS analysis
Cells were fixed in methanol and immunostained with anti-
epithelial-specific  antigen, CD10 and Muc1 antibodies
(Novocastra), at the concentration recommended by the
manufacturer. Incubation was performed for 30 min at room
temperature in Hanks Balanced Salt Solution (HBSS) with
2% FBS, followed by washing in HBSS with 2% FBS. The
same procedure was followed for staining with secondary
antibody, anti-goat IgG or anti-rabbit IgG, labeled with FITC
(1:200 dilution; Jackson Labs). After incubation, cells were
washed once with HBSS (BioWhittaker) and were resus-
pended in HBSS supplemented with 5% FBS. Cells were
stained with 1 µg/ml propidium iodide (Sigma) for 30 min
for DNA cell cycle analysis or for 5 min for viability. Analysis
was performed using FACStarPLUS (Becton Dickinson, Palo
Alto, CA, USA) and the Elite SP (Becton Dickinson) flow
cytometer.
Results
Experimental strategy
In order to investigate the role of the Notch pathway in the
development of the mammary gland, we examined the
effect of agonists and antagonists of Notch signaling on
cell-fate determination utilizing mammary stem/progenitor
cells cultured in suspension, as mammospheres, and differ-
entiated mammary cells, obtained by passaging these cells
on a collagen substratum. The experimental strategy is out-
lined in Fig. 1. The activators and inhibitors of Notch sign-
aling were applied at three different stages of in vitro
development, which we have previously characterized [4].
First, the treatment was applied in suspension culture,
which is enriched in stem/progenitor cells (self-renewal of
stem cells and the proliferation of progenitor cells occur in
these conditions) (Fig. 1a). Second, the treatment was
applied in cultures on collagen substratum, under condi-
tions that promote differentiation of mammosphere-derived
cells (multipotent progenitors commit to a specific lineage)
(Fig. 1b). Finally, the treatment was applied in cultures on a
collagen substratum, using differentiated cells passaged
on a collagen substratum (lineage-restricted progenitors
undergo terminal differentiation) (Fig. 1c).
A synthetic peptide derived from the DSL (Delta-Serrate-
LAG 2) domain conserved in all Notch ligands [9] and a
previously described recombinant Delta 1 ligand fused to
the immunoglobulin Fc fragment (used in combination with
an anti-human Fc antibody, for ligand clustering) [20] were
utilized as agonists of Notch signaling. A Notch4-specific
antibody or a GSI that blocks the intramembranous cleav-
age of Notch, required for signaling [21], was used as theBreast Cancer Research    Vol 6 No 6    Dontu et al.
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antagonist. The synthetic DSL peptide, the recombinant
Delta fused to Fc and GSI are all well characterized with
respect to their effect on Notch signaling [9,20]. We uti-
lized a reporter assay in MCF-7 cells, in which luciferase
expression was driven by the Hes-1 promotor, a gene reg-
ulated by Notch signaling [22], to confirm the ability of acti-
vating or inhibiting ligands to affect Notch signaling.
As shown in Fig. 2a, DSL peptide upregulated Hes-1-
driven luciferase expression. These results are consistent
with previous characterization of these Notch signaling
agonists in reporter assays and in experiments using other
cell types [9]. Notch signaling was blocked using a
Notch4-specific antibody, or a GSI, which abrogates the
intramembranous cleavage of Notch, required for signaling
[19,21]. Both of these inhibitors blocked endogenous Hes-
1-driven luciferase expression, as well as the increase in
luciferase expression induced by the DSL ligand (Fig. 2a).
The specificity of the blocking antibody was confirmed by
successful competition with the antigenic peptide used to
produce the antibody (data not shown). Furthermore, these
effects were dose dependent (Fig. 2b).
Effects of Notch signaling on self-renewal of mammary 
stem cells
We examined the effects of these agonists and antagonists
of Notch signaling on primary, secondary and tertiary mam-
mosphere formation (Fig. 1a). This assay has previously
been used for the in vitro study of neural stem cell self-
renewal [19] and relies on the observation that neuro-
sphere formation is initiated clonally by neural stem cells
[5].
Utilizing retroviral marking studies, we also have demon-
strated that mammospheres are clonally derived and do not
result from cellular aggregation [4]. Primary, secondary,
and tertiary generation mammospheres were formed in the
presence or absence of the Notch-activating DSL peptide.
Although DSL peptide had only modest effects on primary
mammosphere formation, it increased secondary and terti-
ary mammosphere formation 10-fold, compared with con-
trol cultures (Fig. 3a,3b,3d,3e,3g). If this effect was due to
stem cell self-renewal, we would predict that cells derived
from these spheres would retain their multipotent differen-
tiation ability. We therefore examined the ability of second-
ary and tertiary mammosphere-derived cells to clonally
differentiate along the multiple lineages present in the adult
mammary gland.
The adult mammary gland has a lobuloalveolar structure
composed of three cell lineages: myoepithelial cells that
form the basal layer of ducts and alveoli, ductal epithelial
cells that line the lumen of ducts, and alveolar epithelial
cells that synthesize milk proteins [23]. Mammospheres
grown in the presence or absence of Notch agonists or
antagonists were dissociated into single cells and plated at
clonogenic densities on collagen substrata in a medium
that promotes differentiation [4]. After 7 days of cultivation,
the clonally derived colonies were immunostained using lin-
eage-specific markers (epithelial-specific antigen and
cytokeratin 18 for ductal epithelial cells, and cytokeratin 14
and smooth muscle actin for myoepithelial cells). The
number of multipotent cells after one passage was seven
times higher, and that after two passages 100 times higher,
in mammospheres cultured in the presence of DSL,
Figure 1
Effect of modulators of Notch signaling on self-renewal of mammary stem cells and on lineage commitment of mammary progenitor cells: experimen- tal strategy Effect of modulators of Notch signaling on self-renewal of mammary stem cells and on lineage commitment of mammary progenitor cells: experimen-
tal strategy. Treatment was applied (a) to mammospheres in suspension culture, (b) to mammosphere-derived cells cultivated on a collagen substra-
tum, and (c) to differentiated cells cultivated on a collagen substratum. The assay for self-renewal was mammosphere formation. The assay for 
multilineage potential or lineage commitment was lineage-specific immunostaining of clonogenic cultures on the collagen substratum.
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compared with mammospheres cultured without added
DSL. These calculations are based on the number of
spheres (Fig. 3g) and the corresponding percentage of
multilineage colonies, in each experiment (Fig. 3h).
The ability of Notch activating ligands to increase mammos-
phere formation, as well as the production of multilineage
progenitors, suggests that Notch activation promotes
mammary stem cell self-renewal. Similar effects to the DSL
peptide on mammosphere formation were obtained with
recombinant Delta Fc fragment (data not shown). In addi-
tion to increasing the number of mammosphere initiating
cells and bipotent progenitor cells, treatment with Notch
agonists increased their proliferation potential, as shown by
the increased size of mixed lineage colonies, generated
clonally on collagen culture by these cells (Fig. 3i). Treat-
ment with Notch agonists was applied in suspension cul-
ture only, and was not applied to sphere-derived cells
subsequently cultured on collagen substrata, suggesting
that the effect on proliferation is irreversible. This positive
effect of Notch activation on proliferation potential of stem/
progenitor cells also occurs in the mammospheres, as
demonstrated by an increased size of the primary and sec-
ondary mammosphere diameter in the DSL-treated suspen-
sion cultures (mean ± standard error of the mean, 245 ±
11.5 µM versus 130 ± 3 µM; n = 69 and n = 89). This is
due to an increased number of cells per sphere, as demon-
strated by cell counts that are approximately double in
DSL-treated mammospheres compared with control cul-
tures. The viability of cells within a mammosphere was sim-
ilar in the presence of and the absence of DSL. These
results indicate that the Notch activation increases prolifer-
ation of progenitor cells.
In order to further investigate the role of Notch signaling,
and in particular Notch4, in mammary stem cell self-
renewal, we assayed the effect of Notch inhibitors on mam-
mosphere formation. The addition of a Notch4 blocking
antibody to primary cultures had no effect on primary
sphere formation, but completely abolished secondary
mammosphere formation (Fig. 3a,3c,3d,3f,3h). A similar
effect was obtained by blocking Notch activation with a
GSI at 1–5 µM, a concentration found to effectively block
Notch activation in the luciferase reporter assay (Fig. 2a). In
contrast to the effect of adding Notch4 blocking antibody
at the time of mammosphere formation, this treatment had
no effect when added 24–48 hours after mammosphere
formation. This suggests that the effects of Notch activation
on mammary stem cell self-renewal may occur during the
initial stages of mammosphere formation. The cells
responding to modulation of Notch signaling are the sphere
initiating cells, capable of survival and proliferation in
suspension.
Effect of Notch signaling on lineage specification of 
mammary progenitor cells
In other developing systems, Notch signaling has been
shown to effect lineage commitment as well as stem cell
Figure 2
Effect of Notch agonist and antagonist treatment, assessed by Hes-1-driven luciferase expression in MCF-7 cells Effect of Notch agonist and antagonist treatment, assessed by Hes-1-driven luciferase expression in MCF-7 cells. (a) DSL treatment (100 nM) 
increased luciferase expression twofold compared with control, whereas treatment with the N4 blocking antibody (N4Ab) or gamma secretase inhib-
itor (GSI) (5 µM) reduced both endogenous and DSL-induced luciferase expression. (b) Dose–effect of Notch signaling antagonists. The difference 
in luciferase activity in cells treated with the maximum dose of inhibitory agent and in nontreated cells cells was statistically significant for each of the 
four different treatments (P < 0.005). The R2 values and trendlines for the four sets of experiments are shown.
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self-renewal [20,24-26]. The inability of previously
described culture systems of mammary cells to maintain
progenitor cells in an uncommitted state has limited the in
vitro study of lineage commitment. Since we have previ-
ously demonstrated that, in addition to mammary stem
cells, mammospheres contain mammary progenitors capa-
ble of multilineage differentiation, we utilized this system to
determine whether Notch signaling could also act on mam-
mary progenitor cells to affect lineage-specific commit-
ment. In order to test this, we added the DSL peptide to
mammosphere cultures (Fig. 1a), to cultures of mammos-
phere-derived cells on collagen substrata in conditions that
Figure 3
Effect of modulators of Notch signaling on self-renewal of mammary stem cells and on lineage commitment of mammary progenitor cells Effect of modulators of Notch signaling on self-renewal of mammary stem cells and on lineage commitment of mammary progenitor cells. (a)–(g) 
Effect of Notch agonist and antagonist treatment on primary and secondary mammosphere formation. Primary and secondary mammospheres were 
grown in standard conditions (a, d), in the presence of DSL peptide (b, e) and in the presence of N4 blocking antibody (N4Ab) (c, f). Primary mam-
mospheres grown in the presence of N4 antibody (c) are smaller than the control (a). Secondary mammosphere formation is completely blocked by 
treatment with Notch4 blocking antibody (d, f). The addition of DSL peptide increases primary, secondary and tertiary mammosphere formation (a, b, 
d, e, g). Data are presented as the mean ± standard error of the mean. The calculated number of multilineage progenitor cells (number of spheres × 
% multilineage progenitors) shows a sevenfold increase after one passage, and a 100-fold increase after two passages, in mammospheres cultured 
in the presence of DSL compared with mammospheres cultured without added DSL. (h)–(k) Effect of Notch activation on lineage specification of 
human mammary progenitor cells. DSL treatment of mammospheres in suspension culture (DSL1) and on mammosphere-derived cells on the colla-
gen substratum (DSL2) increases the number of myoepithelial progenitors, as shown by the clonogenic assay (h), and increases the rate of prolifer-
ation of bipotent and myoepithelial progenitors, as reflected by the colony size (i). DSL treatment in suspension culture increases the percentage of 
myoepithelial cells, as shown by flow-cytometry analysis (j). Cells were stained red (phycoerythrin [PE]) with myoepithelial marker CD10, and green 
(FITC) with the ductal epithelial marker epithelial-specific antigen (ESA). Treatment with DSL peptide does not have a lineage selective effect on dif-
ferentiated cells, as shown by flow-cytometry analysis of human mammary epithelial cells passaged twice on collagen (k). Data are presented as the 
mean ± standard error of the mean.
+
N4 Ab
+ +
DSL
peptide
Secondary spheres Primary spheres
+ +
0
100
200
300
400
500
600
Control DSL peptide N4 Ab
#
s
p
h
e
r
e
s
/
1
0
,
0
0
0
c
e
l
l
s
Primary spheres
Secondary sphe
Tertiary spheres
(g) (a) (b) (c) (d) (e) (f)
0
500
1000
1500
2000
2500
Control DSL 1 DSL 2
C
o
l
o
n
y
s
i
z
e
(
a
v
g
#
o
f
c
e
l
l
s
/
c
o
l
)
Mixed
Epithelilal
Myoepithelial
(i)
0
10
20
30
40
50
60
70
80
90
100
Control DSL 1 DSL 2
C
o
l
o
n
y
t
y
p
e
(
%
)
Mixed
Epithelial
Myoepithelial
(h)
0
10
20
30
40
50
60
70
ESA Muc 1 CD10
%
p
o
s
i
t
i
v
e
c
e
l
l
s
Control
DSL peptide
0
10
20
30
40
50
60
70
80
90
100
Control DSL
C
e
l
l
t
y
p
e
(
%
)
Ductal epithelial-green
Myoepithelial-red
(j) (k)Available online http://breast-cancer-research.com/content/6/6/R605
R611
promote their differentiation (Fig. 1b) or to cultures of differ-
entiated cells (Fig. 1c).
Cells were assayed for lineage-specific commitment, using
the clonogenic assay described earlier. As shown in Fig. 3h
(DSL1), the percentage of myoepithelial progenitor cells
generated by DSL-treated mammospheres was increased
approximately 13-fold compared with cells from mammos-
pheres cultured in the absence of DSL ligand. The percent-
age of myoepithelial progenitor cells generated by
mammosphere-derived cells treated with DSL starting from
the moment of their plating on collagen culture (DSL2) gen-
erated sevenfold more myoepithelial progenitor cells com-
pared with controls. The significant effect of DSL peptide,
when added only to suspension-cultured mammospheres,
suggests that Notch activation increased the number of
myoepithelial progenitors and/or their rate of proliferation in
an irreversible manner. The increased size of myoepithelial
and bilineage colonies (Fig. 3i) formed in the presence of
DSL peptide suggests that Notch stimulation may promote
proliferation of myoepithelial and bilineage progenitors.
In order to determine whether the increase in colony size
results from an effect of Notch on cell survival, we used pro-
pidium iodide staining in the same clonogenic assay. Treat-
ment with DSL peptide did not have a discernable effect on
the cell-death rate of either ductal epithelial cells or myoep-
ithelial cells. To assess more accurately the increase in total
number of myoepithelial cells upon treatment with DSL in
suspension culture, we repeated the same experiment
described earlier, utilizing flow cytometry analysis, to quan-
titate the cell lineage (Fig. 3j). The results showed a 15-fold
increase in myoepithelial cells upon addition of DSL pep-
tide to the culture.
Effect of Notch signaling on differentiated mammary 
epithelial cells
In contrast to the significant effects of Notch signaling on
uncommitted mammary cells, modulation of the Notch
pathway had no significant effect on differentiated mam-
mary epithelial cells. The addition of DSL peptide to differ-
entiated cells cultured on collagen substrata (Fig. 1c) had
no effect on lineage specification, as shown by flow-cytom-
etry analysis using lineage-specific markers (Fig. 3k). Fur-
thermore, the addition of Notch antibody or the GSI at 1–
10 µM had no significant effect on cell number or lineage
commitment (data not shown). This also demonstrates that
Notch activation is not necessary for the survival of fully dif-
ferentiated mammary cells.
Effect of Notch signaling on branching morphogenesis
It has previously been demonstrated that culture of human
or rodent mammary cells in reconstituted basement mem-
brane (Matrigel) promotes morphogenic differentiation
[18,27]. Since mammospheres are composed of undiffer-
entiated mammary cells, we have utilized three-dimensional
Matrigel cultures to explore the morphogenic differentiation
potential of these cells. Following 3–4 weeks of cultivation
in Matrigel, mammospheres develop extensive ductal lobu-
loalveolar structures similar in morphology to those found in
vivo (Fig. 4a,4b). We utilized this system to examine the
role of Notch signaling in morphogenesis. Secondary mam-
mospheres were imbedded in Matrigel and treated with
DSL peptide, Notch4 antibody or GSI. Treatment with DSL
peptide promoted earlier development, as well as
increased length and number of branching structures, com-
pared with control cultures (Fig. 4c,4d). In contrast, the
Notch4 antibody completely inhibited branching morpho-
genesis (Fig. 4c,4d). Similar effects were produced by
blocking Notch signaling with GSI (data not shown).
Expression of Notch4 in human mammary epithelial cells 
in vitro
We and other workers have found that expression of Notch
receptors in the adult human mammary gland was below
the level of detection using immunostaining of tissue sec-
tions, but was detectable by RT-PCR [28]. Moreover,
expression of Notch4 in dissociated mammary tissue was
below the level of detection using flow cytometry. The
experiments already described, however, suggested that
Notch receptors are present in mammary stem cells and
progenitor cells, and are downregulated in differentiated
cells. Previous gene expression profile analysis by micro-
array and real-time RT-PCR showed that mammosphere-
derived cells passaged in suspension culture express all
Notch receptors at a higher level (twofold to fourfold) than
the same cells cultured under conditions that induce differ-
entiation [4].
These results suggest that Notch receptors are expressed
at higher levels in more primitive mammary cells, such as
those found in the developing mammary gland, compared
with the mature gland. To test this hypothesis, we immu-
nostained structures generated by mammospheres in
Matrigel culture, at different stages of growth (between 4
days and 2 weeks). We found that cells expressing Notch4
were uniformly distributed in spherical structures at the
beginning of cultivation (Fig. 5a,5b). As branching morpho-
genesis occurred, Notch4 expression became limited to
the subterminal end of branches (Fig. 5c,5d). The corre-
sponding areas in vivo have previously been postulated to
contain mammary stem cells and progenitor cells [23].
Discussion
In order to study the role of Notch signaling in mammary
cell-fate determination, we have utilized an experimental
system that allows the analysis of cell self-renewal and dif-
ferentiation in vitro. This enabled us to study the effect of
Notch activation and inhibition at a single cell level and
under conditions where the timing and the duration ofBreast Cancer Research    Vol 6 No 6    Dontu et al.
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Notch signaling could be controlled. Our findings suggest
that Notch signaling regulates cell-fate decisions in the
mammary gland at several distinct developmental stages.
We propose that in the mammary gland, as has been
reported in other developmental systems, Notch activation
acts as a regulator of asymmetric cell-fate decisions. Notch
activation promotes self-renewal in stem cells, whereas in
later stages of development it biases cell-fate decisions in
mammary progenitor cells towards adoption of a myoepi-
thelial cell fate versus an epithelial cell fate.
The increase in the number of mammosphere-initiating cells
reflects an increase in the number of cells capable of self-
renewal, in the experimental system used in this study. The
effect of Notch activation on mammosphere formation
underscores the value of the mammosphere cultivation sys-
tem in studying in vitro self-renewal regulation. It has previ-
ously been shown in suspension culture that neural stem
cells can generate mixed colonies, termed neurospheres,
composed of stem cells and progenitor cells. We have
demonstrated that mammospheres are composed of stem
cells and progenitor cells capable of self-renewal and mul-
tilineage differentiation [4]. Our clonal analysis of individual
cells from single spheres suggested that mammospheres
are composed of approximately 150–200 progenitor cells,
which cannot generate new spheres but have bilineage or
trilineage differentiation potential, and of one or two puta-
tive stem cells able to generate a new sphere with the same
cellular composition as the parental sphere.
Figure 4
Effect of Notch signaling on branching morphogenesis Effect of Notch signaling on branching morphogenesis. (a) Fragment of the human mammary gland, after 8 hours of collagenase digestion of the 
reduction mammoplasty sample. (b) Complex ductal–alveolar structure developed in 18 days, from a mammosphere embedded in Matrigel. (c) Sec-
ondary mammospheres were embedded in Matrigel and treated with DSL peptide or Notch4 blocking antibody (N4Ab). Longer branches developed 
earlier in the presence of DSL peptide. (d) In addition, more spheres developed branching structures. The Notch4 blocking antibody completely 
inhibited proliferation and branching in Matrigel (c, d). Images shown in (c) are representative of 100–150 structures per experiment, scored in three 
different experiments with cells derived from three different patients. Data are presented as the mean ± standard error of the mean.
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The constant frequency of sphere formation during multiple
passages, observed in passages of both individual and
pooled mammospheres, suggests that only asymmetric
self-divisions or a small number of symmetric self-renewal
divisions contribute to sphere formation (Fig. 6a). If bipo-
tent or monopotent progenitor cells were able to survive in
suspension, they would generate mammospheres of
increasingly smaller size and, eventually, they would stop
growing in suspension after several passages (Fig. 6b),
which did not occur in the experimental setting used here.
An increase in the number of symmetric self-renewal divi-
sions would result in an amplification of the cellular popula-
tion, by progressively increasing the number of
mammospheres at each passage (Fig. 6c). This effect was
obtained upon exogenous activation of Notch signaling. In
this discussion we adopted the operational definition of
stem cells as the only normal cells capable of self-renewal
[29,30].
Treatment with Notch agonists increased the commitment
of bilineage progenitors to myoepithelial lineage, when
applied early in suspension culture (Fig. 1, DSL1) or later
on collagen culture (Fig. 1, DSL2). The effect on lineage
commitment appears to be irreversible, since early activa-
tion of Notch, in suspension culture, resulted in an increase
in the number of myoepithelial progenitors – although the
treatment with Notch agonists was not maintained on
collagen cultures. In addition to an increase in the number
of bipotent and myoepithelial progenitor cells, treatment
with Notch agonists resulted in a significant increase in the
size of both mixed and myoepithelial colonies. This sug-
gests that Notch activation increases the proliferation
potential of both bipotent and myoepithelial progenitors.
These effects are irreversible and may involve an instructive
mechanism or the selective proliferation of myoepithelial
cells. In contrast to the effects of Notch signaling on mam-
mary stem cells and progenitor cells, activation or inhibition
of these pathways in fully differentiated mammary cells had
no apparent effect.
The increased branching we observed in the three-dimen-
sional cultivation system upon Notch activation is consist-
ent with previous studies demonstrating that proliferation of
myoepithelial cells can facilitate branching morphogenesis.
Moreover, Notch signaling appears to be absolutely
required for branching and growth in three-dimensional cul-
tures as development of branching structures is completely
blocked by Notch4 antibody or GSI. The expression of
Notch4 protein in the growing mammary tree in vitro is also
consistent with an important role of Notch signaling in mor-
phogenesis of the mammary gland. The apparent discrep-
ancy between our results and the previous findings by
Uyttendaele and colleagues [13] (who showed that overex-
pressing Notch4 in the mouse mammary epithelial TAC-2
cell line prevented branching morphogenesis in response
to hepatocyte growth factor or transforming growth factor
beta) underscores the importance of the experimental sys-
tems utilized. This discrepancy may be accounted for by
differences in the experimental systems, such as the use of
an immortalized mouse epithelial cell line in the Uyttendaele
study compared with primary normal human cells in our
study. Furthermore, Uyttendaele and colleagues utilized
overexpression of activated Notch, whereas we used exog-
enous modulation of the Notch pathway.
Smith and colleagues [12] demonstrated that Notch4 has
an important role in both normal mammary development
and carcinogenesis. Transgenic mice harboring a constitu-
tively active Notch4 under mouse mammary tumor virus
promoter regulation exhibited arrested mammary gland
development, and eventually developed poorly differenti-
ated adenocarcinomas. Questions remain in interpreting
the report that the Notch4 knockout mouse has no appar-
ent defect in mammary gland development [31]. This may
indicate that in vivo there are compensatory mechanisms
absent in our in vitro experimental system. Alternatively, the
expression or activity of different homologs of Notch can be
interdependent, as suggested by previous studies [32].
Conclusions
Our findings regarding the role of Notch in promoting self-
renewal of mammary stem cells, in addition to previous
observations that it can function as a proto-oncogene
[15,16,28,33-38], suggest that abnormal Notch signaling
may be involved in carcinogenesis, through deregulation of
normal mammary stem cell self-renewal. Indeed, it has
Figure 5
Notch4 protein detected by immunostaining (FITC-green) in structures  derived from mammospheres embedded in Matrigel Notch4 protein detected by immunostaining (FITC-green) in structures 
derived from mammospheres embedded in Matrigel. (a),(b) Spherical 
structures at 5 days of cultivation (Nomarski contrast-phase image and 
immunofluorescence). (c),(d) Branching structures at 16 days of 
cultivation.
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recently been proposed that stem cells or early progenitor
cells constitute the primary targets of transformation [2].
We have recently described the existence of a tumorigenic
subset of human breast carcinoma cells, with a definable
phenotype, which is responsible for tumor formation as well
as for generating the phenotypic heterogeneity found in
breast cancers [39]. Tumorigenic cells, like their normal
stem cell counterparts, can therefore undergo self-renewal
as well as differentiation, albeit aberrant. We have postu-
lated that the tumor stem cell population drives tumorigen-
esis, recurrence and metastasis [40].
In addition to our findings regarding the role of Notch in
self-renewal of mammary stem cells, these findings suggest
that carcinogenesis may involve the deregulation of proc-
esses involved in normal stem cell self-renewal. Elucidation
of key elements of these pathways may identify new targets
for cancer therapy [32].
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